Pyxis Oncology (NASDAQ:PYXS – Get Free Report) was upgraded by equities research analysts at William Blair from a “market perform” rating to an “outperform” rating in a report released on Friday, MarketBeat.com reports.
Several other research firms also recently issued reports on PYXS. Wedbush dropped their target price on Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating on the stock in a research report on Friday, November 6th. Royal Bank Of Canada lifted their price target on Pyxis Oncology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, November 6th. HC Wainwright boosted their price objective on Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Stifel Nicolaus set a $5.00 price objective on Pyxis Oncology in a report on Thursday, November 5th. Finally, Weiss Ratings upgraded Pyxis Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.71.
Read Our Latest Report on Pyxis Oncology
Pyxis Oncology Price Performance
NASDAQ PYXS opened at $1.68 on Friday. The company’s 50 day moving average is $2.16 and its 200-day moving average is $2.15. Pyxis Oncology has a 12-month low of $1.03 and a 12-month high of $5.55.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, equities analysts expect that Pyxis Oncology will post -1.12 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its holdings in shares of Pyxis Oncology by 221.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 147,598 shares of the company’s stock valued at $344,000 after acquiring an additional 101,698 shares in the last quarter. Jump Financial LLC purchased a new position in shares of Pyxis Oncology during the third quarter worth about $150,000. Empowered Funds LLC purchased a new position in shares of Pyxis Oncology during the third quarter worth about $219,000. Blue Owl Capital Holdings LP purchased a new position in shares of Pyxis Oncology during the third quarter worth about $2,330,000. Finally, Commonwealth Equity Services LLC increased its position in shares of Pyxis Oncology by 14.8% in the third quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock worth $114,000 after purchasing an additional 6,295 shares during the last quarter. 39.07% of the stock is currently owned by hedge funds and other institutional investors.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.
Further Reading
- Five stocks we like better than Pyxis Oncology
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
